148 related articles for article (PubMed ID: 34551570)
1. Evaluation of safety and efficacy of apatinib combination with chemotherapy for ovarian cancer treatment: a systematic review and meta-analysis.
Qi J; Liu E; Yue H; Chen G; Liu Y; Chen J
Ann Palliat Med; 2021 Sep; 10(9):9902-9913. PubMed ID: 34551570
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Combination Therapy of Transarterial Chemoembolization and Apatinib for Unresectable Hepatocellular Carcinoma in the Chinese Population: A Meta-Analysis.
Wei Y; Liu J; Yan M; Zhao S; Long Y; Zhang W
Chemotherapy; 2019; 64(2):94-104. PubMed ID: 31569090
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis.
Cheng H; Sun A; Guo Q; Zhang Y
Drug Des Devel Ther; 2018; 12():2173-2183. PubMed ID: 30034222
[TBL] [Abstract][Full Text] [Related]
4. Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer.
Liu H; Li Y; Yao Y; Chen K; Gan J
Dis Markers; 2022; 2022():6971717. PubMed ID: 36193493
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis.
Gong A; Li X
World J Surg Oncol; 2022 Mar; 20(1):69. PubMed ID: 35246145
[TBL] [Abstract][Full Text] [Related]
6. The combination of apatinib and S-1 for the treatment of advanced gastric cancer in China: A meta-analysis of randomized controlled trials.
Liu Y; Zhou C; Zhang K; Feng Y; Zhang R
Medicine (Baltimore); 2018 Nov; 97(47):e13259. PubMed ID: 30461630
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis.
Peng D; Cai Y; Chen G; Hou M; Luo X; Dongzhi Z; Xie H; Liu Y
Front Pharmacol; 2023; 14():1101063. PubMed ID: 37153777
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of apatinib combined with radiotherapy in the treatment of advanced pancreatic cancer: a meta-analysis.
Ma Y; Li J; Wen L; Zhang G; Yao X
World J Surg Oncol; 2023 Jun; 21(1):165. PubMed ID: 37264386
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis.
Long Z; Huang M; Liu K; Li M; Li J; Zhang H; Wang Z; Lu Y
Front Oncol; 2021; 11():662318. PubMed ID: 33816318
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Low-Dose Apatinib Combined with Chemotherapy as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis.
Wang L; Li J; Chen H
Chemotherapy; 2024; 69(1):11-22. PubMed ID: 37339610
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients.
Yao H; Chen X; Tan X
BMC Cancer; 2021 Apr; 21(1):449. PubMed ID: 33892656
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.
Lin H; Weng X; Wu X; Wu L
Transl Cancer Res; 2022 Jun; 11(6):1770-1780. PubMed ID: 35836539
[TBL] [Abstract][Full Text] [Related]
14. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
[No Abstract] [Full Text] [Related]
15. Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of liver cancer: a systematic review and single-arm meta-analysis.
Chen M; Li Y; Cheng M
BMC Gastroenterol; 2024 Jan; 24(1):55. PubMed ID: 38297195
[TBL] [Abstract][Full Text] [Related]
16. Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
Yang G; Xu H; Yang L; Xu F; Zhang S; Yang Y; Wang Y
Lung Cancer; 2020 Sep; 147():229-236. PubMed ID: 32739743
[TBL] [Abstract][Full Text] [Related]
17. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Liu ZL; Zhu WR; Zhou WC; Ying HF; Zheng L; Guo YB; Chen JX; Shen XH
J Integr Med; 2014 Jul; 12(4):346-58. PubMed ID: 25074884
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
Chen W; Li Z; Zheng Z; Wu X
Cancer Med; 2020 Aug; 9(16):5899-5907. PubMed ID: 32627959
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
[No Abstract] [Full Text] [Related]
20. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
Wu Q; Fu Y; Wen W; Xi T; Zhao G
J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]